{"schema_version":"secwatch.filing_event.v1","accession":"0000950103-25-007061","form_type":"8-K","ticker":"ADCT","cik":"0001771910","company_name":"ADC Therapeutics SA","filed_at":"2025-06-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.653371+00:00","generated_at":"2026-05-19T22:24:26.178136+00:00","sec_items":["5.07","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"ADC Therapeutics elects Timothy Coughlin to board at 2025 AGM; all proposals pass","bullets":["Timothy Coughlin elected to board; CPA, former Neurocrine CFO, appointed audit committee chair.","Binding votes: board max comp $2.3M, exec fixed $2.6M, variable $3.5M.","Amendment to 2019 Equity Incentive Plan approved to increase authorized shares.","Articles of association amended to raise conditional share capital for employee participation.","All 12 shareholder proposals, including director elections and say-on-pay, approved."],"urls":{"canonical":"https://secwatch.observer/filing/0000950103-25-007061","json":"https://secwatch.observer/filing/0000950103-25-007061.json","markdown":"https://secwatch.observer/filing/0000950103-25-007061.md","text":"https://secwatch.observer/filing/0000950103-25-007061.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1771910/000095010325007061/0000950103-25-007061-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1771910/000095010325007061/dp229762_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T22:24:26.178136+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}